A study to test Aumolertinib in European participants with genetically linked advanced Lung Cancer

2024-519618-29-00 Protocol HS-10296-108 Human pharmacology (Phase I) - Other Ended

Start 8 Apr 2025 · End 18 Jul 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol HS-10296-108

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 20
Countries 1
Sites 1

Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations

Key facts

Sponsor
Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
8 Apr 2025 → 18 Jul 2025
Decision date (initial)
2025-03-27
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations

VersionLevelCodeTermSystem organ class
27.1 PT 10061873 Non-small cell lung cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Jiangsu Hansoh Pharmaceutical Group Co. Ltd.

Sponsor organisation
Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
Address
No. 9 Dongjin Road, Economic And Technical Development Zone Economic And Technical Development Zone
City
Lianyungang
Postcode
222069
Country
China

Scientific contact point

Organisation
Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
Contact name
Shaonan Fan

Public contact point

Organisation
Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
Contact name
Shaonan Fan

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 3 1
Rest of world
Serbia, Bosnia and Herzegovina, Moldova, Republic of
17

Investigational sites

Bulgaria

1 site · Ended
Multispecialty hospital for active treatment Sveta Sofia EOOD
40001: Department of medical Oncology, Bulevard Bilgariya 104, 1404, Sofiya

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2025-04-08

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-12-06 Bulgaria Acceptable
2025-03-24
2025-03-27
2 SUBSTANTIAL MODIFICATION SM-1 2025-05-26 Bulgaria Acceptable
2025-08-13
2025-08-14